Merck Analysts Slash Their Forecasts After Q2 Results
Portfolio Pulse from Avi Kapoor
Merck & Co Inc (NYSE:MRK) reported better-than-expected Q2 earnings and sales, but revised its full-year 2024 forecasts downward. Analysts from UBS, Wells Fargo, and B of A Securities lowered their price targets for Merck following the earnings announcement.
July 31, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Merck reported better-than-expected Q2 earnings and sales but revised its full-year 2024 forecasts downward. Analysts from UBS, Wells Fargo, and B of A Securities lowered their price targets for Merck.
Despite beating Q2 earnings expectations, Merck's downward revision of its full-year 2024 forecasts and the subsequent lowering of price targets by multiple analysts suggest a negative short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100